香港股市今日开盘，荣昌生物（09995.HK）股价盘中大跌5.01%，引发市场关注。据悉，该跌幅与公司最新公布的配股计划密切相关。
根据荣昌生物发布的公告，公司计划配售1900万股新H股，配售价为每股42.44港元，较5月21日收市价46.90港元折让约9.51%。此次配股将占经扩大后已发行H股数目的约9.11%，以及配售股份配发及发行后经扩大已发行股份总数的约3.37%。公司预计通过此次配股募集资金净额约7.96亿港元。
荣昌生物表示，此次募集的资金将主要用于投资其核心产品泰它西普（RC18）的核心适应症拓展，包括重症肌无力、膜性肾病等，以及其他一般企业用途。这一举措显示了公司在加强核心产品研发和市场拓展方面的决心。然而，由于新股发行价格较现有股价有较大折扣，投资者担心可能造成股权稀释，因此引发了股价的大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.